AGIO
Agios Pharmaceuticals, Inc.
$31.81
-0.11
(-0.34%)
Mkt Cap
1.90B
Volume
722,276
52W Range
22.24-46
Sector
Healthcare
Beta
0.63
EPS (TTM)
-7.01 USD
P/E Ratio
-3.82
Revenue (TTM)
98.34M USD
Rev Growth (5Y)
-2.8%
EPS Growth (5Y)
N/A
Company Description
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 54.03M | 36.50M | 26.82M | 14.24M | 0 | 0 | 117.91M | 94.39M | 43.01M | 69.89M | 59.12M | 65.36M |
| Net Income | (412.78M) | 673.73M | (352.09M) | (231.80M) | 1.60B | (327.37M) | (411.47M) | (346.03M) | (314.67M) | (198.47M) | (117.73M) | (53.50M) |
| EPS | -7.12 | 11.86 | -6.33 | -4.23 | -6.36 | -4.74 | -6.61 | -6.03 | -6.75 | -5.07 | -3.15 | -1.59 |
| Free Cash Flow | (377.29M) | (391.53M) | (297.06M) | (314.36M) | (413.06M) | (304.87M) | (382.79M) | (311.41M) | (289.86M) | 28.65M | (97.11M) | (61.57M) |
| FCF / Share | -6.51 | -6.89 | -5.34 | -5.74 | -6.83 | -4.42 | -6.38 | -5.42 | -6.22 | 0.73 | -2.59 | -1.83 |
| Operating CF | (372.98M) | (389.84M) | (296.06M) | (309.48M) | (407.32M) | (290.76M) | (370.62M) | (304.42M) | (285.23M) | 38.56M | (76.95M) | (59.35M) |
| Total Assets | 1.30B | 1.66B | 937.12M | 1.24B | 1.44B | 852.95M | 890.74M | 858.46M | 614.40M | 619.09M | 420.06M | 491.90M |
| Total Debt | 40.21M | 56.99M | 72.00M | 85.66M | 97.09M | 105.20M | 113.66M | 0 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 89.13M | 76.25M | 88.20M | 139.26M | 203.13M | 127.44M | 80.93M | 805.42M | 567.75M | 573.56M | 375.91M | 14.03M |
| Book Value | 1.19B | 1.54B | 811.02M | 1.10B | 1.29B | 399.50M | 640.53M | 687.54M | 375.50M | 358.59M | 345.12M | 424.37M |
| Return on Equity | -0.35 | 0.44 | -0.43 | -0.21 | 1.24 | -0.82 | -0.64 | -0.50 | -0.84 | -0.55 | -0.34 | -0.13 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 44.74M | 20.75M | 19.97M | 12.88M | 12.46M | 8.73M | 10.73M | 8.96M | 8.62M | 8.19M | 7.10M | 7.40M |
| Net Income | (100.70M) | (99.11M) | (108.04M) | (103.43M) | (112.02M) | (89.29M) | (96.52M) | 947.91M | (96.12M) | (81.55M) | (95.94M) | (91.32M) |
| EPS | -1.69 | -1.69 | -1.85 | -1.78 | -1.93 | -1.55 | -1.69 | 16.65 | -1.69 | -1.45 | -1.72 | -1.64 |
| Free Cash Flow | (58.52M) | (119.69M) | (97.33M) | (89.71M) | (78.00M) | (112.25M) | (134.13M) | (84.64M) | (72.75M) | (100.01M) | (72.72M) | (62.01M) |
| FCF / Share | -0.98 | -2.04 | -1.67 | -1.54 | -1.35 | -1.95 | -2.35 | -1.49 | -1.28 | -1.77 | -1.30 | -1.11 |
| Operating CF | (57.31M) | (118.92M) | (96.21M) | (88.15M) | (77.12M) | (111.49M) | (133.17M) | (84.22M) | (72.59M) | (99.87M) | (72.49M) | (61.64M) |
| Total Assets | 1.11B | 1.18B | 1.30B | 1.39B | 1.47B | 1.56B | 1.66B | 1.79B | 773.06M | 849.71M | 937.12M | 1.01B |
| Total Debt | 31.17M | 35.74M | 40.21M | 44.52M | 48.76M | 52.94M | 56.99M | 60.83M | 64.62M | 68.35M | 72.00M | 75.50M |
| Cash & Equiv | 99.65M | 113.60M | 89.13M | 92.71M | 80.87M | 78.96M | 76.25M | 253.73M | 84.52M | 118.76M | 88.20M | 64.33M |
| Book Value | 1.03B | 1.11B | 1.19B | 1.28B | 1.37B | 1.47B | 1.54B | 1.63B | 660.51M | 743.92M | 811.02M | 886.84M |
| Return on Equity | -0.10 | -0.09 | -0.09 | -0.08 | -0.08 | -0.06 | -0.06 | 0.58 | -0.15 | -0.11 | -0.12 | -0.10 |
AGIO News
Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET
AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know
Agios' Growth Story Hinges on Mitapivat's Commercial Expansion
Bank of New York Mellon Corp Invests $7.37 Million in Agios Pharmaceuticals, Inc. $AGIO
Agios Pharmaceuticals: Indication Stacking Is Creating A Commercial Flywheel
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
Assenagon Asset Management S.A. Has $3.86 Million Stock Holdings in Agios Pharmaceuticals, Inc. $AGIO
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO